21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results

BACKGROUND: Refractory or resistant (R/R) cytomegalovirus (CMV) infection after hematopoietic cell transplant (HCT) and solid organ transplant (SOT) cause serious, potentially fatal complications; therapeutic options are limited. In a Phase 3 study (NCT02931539), maribavir (MBV) was superior to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Marcus, Cervera, Carlos, Kotton, Camille, Sasadeusz, Joseph, Wu, Jingyang, Fournier, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644079/
http://dx.doi.org/10.1093/ofid/ofab466.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644079/
http://dx.doi.org/10.1093/ofid/ofab466.021

Ejemplares similares